Mithridate (Genk 2023) is a Belgian biotechnology start-up company developing state of the art therapeutic solutions in the field of thrombosis & hemostasis. We design and engineer innovative therapeutic proteins by using a single domain antibody (sdAb or nanobody^®) conjugation platform, sometimes combined with AI-assisted design.

State of the art molecular tools, diagnostics, laboratories and extensive knowledge on hemostasis and thrombosis are at Mithridate’s disposal via a close collaboration with Synapse Research Institute (Maastricht the Netherlands). Currently, Mithridate’s development pipeline consists of engineered sdAb ± enzyme constructs that were created at the Synapse Research Institute in Maastricht and further developed as therapeutic Constructs at Mithridate.